UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT ~~PURSUANT TO SECTION 13 OR 15(d)~~

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 7, 2025

Date of Report (Date of earliest event reported): June 2, 2025

Akoya Biosciences, Inc.

(Exact name of registrant as specified in its charter)


Delaware	001-40344	47-5586242
Delaware		001-40344	47-5586242
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
(State or other jurisdictionof incorporation)		(CommissionFile Number)	(IRS EmployerIdentification No.)

100 Campus Drive, 6th Floor Marlborough, MA (Address of principal executive offices) 01752 (Zip Code)


100 Campus Drive, 6th FloorMarlborough, MA		01752
(Address of principal executive offices)		(Zip Code)

(855) 896-8401

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

~~☒Written~~¨ ~~communications~~Soliciting material pursuant to Rule ~~425~~14a-12 under the ~~Securities~~Exchange Act (17 CFR ~~230~~240.~~425~~14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

~~☐Soliciting~~¨ ~~material~~Pre-commencement communications pursuant to Rule ~~14a~~13e-124(c) under the Exchange Act (17 CFR 240.~~14a~~13e-124(c))

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common stock, par value $0.00001 per share		AKYA		The Nasdaq Stock Market LLC


Title of each class	Trading Symbol	Name of each exchange on which registered
Common stock, par value $0.00001 per share	AKYA	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company x

~~Emerging~~If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section ☒13(a) of the Exchange Act. ¨

Item 5.07 Submission of Matters to a Vote of Security Holders.

IfOn anJuly ~~emerging~~7, ~~growth~~2025, ~~company~~Akoya Biosciences, ~~indicate~~Inc. by(the ~~check~~“Company,” ~~mark~~“we,” if“us,” or “our”) held a special meeting of its stockholders (the ~~registrant~~“Special ~~has~~Meeting”). ~~elected~~Of ~~not~~the to49,954,210 ~~use~~shares of our common stock issued and outstanding at the ~~extended~~close ~~transition~~of business ~~period~~June 5, 2025, the record date for ~~complying~~the ~~with~~Special ~~any~~Meeting, ~~new~~42,421,181 shares were represented in person or ~~revised~~by ~~financial~~proxy, ~~accounting~~representing approximately ~~standards~~85% ~~provided~~of ~~pursuant~~the tooutstanding ~~Section~~shares ~~13(a)~~as of the ~~Exchange~~record ~~Act~~date, constituting a quorum for all matters to be presented at the Special Meeting. ☐

Two proposals were submitted to our stockholders for a vote at the Special Meeting. The proposals are described in detail in the definitive proxy statement for the Special Meeting filed with the Securities and Exchange Commission on June 16, 2025. Below is a brief description of, and the final results of the votes for, each proposal:

Proposal 1: Our stockholders approved the proposal to adopt the Amended and Restated Agreement and Plan of Merger, dated as of April 28, 2025, by and among Quanterix Corporation, Wellfleet Merger Sub, Inc. and Akoya Biosciences, Inc. (the “Akoya Merger Proposal”).

Votes For		Votes Against		Abstentions		Broker Non-Votes
42,261,529		97,486		62,166		-

Proposal 2: Our stockholders approved the proposal to adjourn the Special Meeting from time to time, if necessary or appropriate, including to solicit additional proxies in favor of the Akoya Merger Proposal if there are insufficient votes at the time of such adjournment to approve the Akoya Merger Proposal.

Item 8.01 Other Events

Votes For		Votes Against		Abstentions		Broker Non-Votes
41,986,179		340,995		94,007		-

However, because the Akoya Merger Proposal was approved, the adjournment of the Special Meeting was not necessary to continue to solicit additional proxies and, accordingly, the Special Meeting was not adjourned.

As previously disclosed, on April 28, 2025, Akoya Biosciences, Inc., a Delaware corporation (“Akoya”), entered into an Amended and Restated Agreement and Plan of Merger (the “A&R Merger Agreement”) with Quanterix Corporation, a Delaware corporation (“Quanterix”) and Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Quanterix (“Merger Sub”), pursuant to which, subject to the terms and conditions set forth therein, Merger Sub will merge with and into Akoya (the “Merger”), with Akoya surviving such Merger as a wholly owned subsidiary of Quanterix. 2

SIGNATURES

OnPursuant ~~May 20, 2025, Akoya announced that it received an unsolicited acquisition proposal (the “Unsolicited Proposal”) from a third party (“Party A”)~~ to ~~acquire Akoya in an all cash tender offer transaction. Under~~ the ~~terms~~ requirements of the Securities ~~Unsolicited~~Exchange ~~Proposal,~~Act ~~each share~~ of ~~Akoya common stock would be exchanged for $1.40 in cash at the completion of the transaction contemplated by the Unsolicited Proposal. Also as previously disclosed~~1934, ~~Akoya’s board of directors (~~the ~~“Akoya~~registrant ~~Board”)~~has ~~determined,~~duly after consultation with its financial advisor and outside legal counsel, that the Unsolicited Proposal could reasonably be expected to lead to a “Superior Proposal” (as defined in the A&R Merger Agreement), and therefore caused ~~Akoya~~this toreport ~~engage in discussions with Party A concerning the Unsolicited Proposal. Such discussions included, among other things, mutual access~~ to ~~non-public~~be ~~information~~signed ~~and~~on ~~data,~~its abehalf ~~request~~ by ~~Akoya for a draft definitive agreement, and a request by Akoya to improve~~ the ~~terms~~undersigned hereunto ofduly ~~the Unsolicited Proposal for the Akoya Board’s consideration in determining whether such revised proposal could constitute a “Superior Proposal~~authorized.”

Date: July 7, 2025	Akoya Biosciences, Inc.

	By:	/s/ Brian McKelligon
		Brian McKelligon
		Chief Executive Officer

~~On June 2, 2025, Akoya announced that following those discussions, Party A declined to revise the Unsolicited Proposal and withdrew the Unsolicited Proposal.~~3

The Akoya Board continues to recommend the adoption of the A&R Merger Agreement to the Akoya stockholders for the reasons set forth in the section titled “Akoya’s Reasons for the Merger and Recommendation of the Akoya Board” set forth in the Post-Effective Amendment No. 1 to Form S-4 filed by Quanterix on May 21, 2025. Akoya and the Akoya Board remain fully committed to completing the Merger on the terms set forth in the A&R Merger Agreement.

Important Additional Information

In connection with the proposed Merger, Quanterix has filed with the SEC a post-effective amendment to its registration statement on Form S-4 (as so amended, the “Registration Statement”), which contains a preliminary proxy statement of Akoya and a preliminary prospectus of Quanterix (the “Proxy Statement/Prospectus”), and each of Quanterix and Akoya have, and may in the future, file with the SEC other relevant documents regarding the proposed Merger. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT AND THE PROXY STATEMENT/PROSPECTUS CAREFULLY AND IN THEIR ENTIRETY AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC BY QUANTERIX AND AKOYA, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT QUANTERIX, AKOYA AND THE PROPOSED MERGER. A definitive copy of the Proxy Statement/Prospectus will be mailed to Akoya stockholders when that document is final. Investors and security holders will be able to obtain the Registration Statement and the Proxy Statement/Prospectus, as well as other filings containing information about Quanterix and Akoya, free of charge from Quanterix or Akoya or from the SEC’s website when they are filed. The documents filed by Quanterix with the SEC may be obtained free of charge at Quanterix’s website, at www.quanterix.com, or by requesting them by mail at Quanterix Investor Relations, 900 Middlesex Turnpike, Billerica, MA 01821. The documents filed by Akoya with the SEC may be obtained free of charge at Akoya’s website, at www.akoyabio.com, or by requesting them by mail at Akoya Biosciences, Inc., 100 Campus Drive, 6th Floor, Marlborough, MA 01752 ATTN: Chief Legal Officer.

Participants in the Solicitation

Quanterix and Akoya and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Akoya in respect of the proposed Merger. Information about Akoya’s directors and executive officers is available in the Proxy Statement/Prospectus and in Amendment No. 1 to

Akoya’s Annual Report on Form 10-K for fiscal year ended December 31, 2024, filed with the SEC on April 28, 2025, and other documents filed by Akoya with the SEC. Other information regarding the persons who may, under the rules of the SEC, be deemed participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, is contained in the Proxy Statement/Prospectus and other relevant materials to be filed with the SEC regarding the proposed Merger when they become available. Investors should read the definitive Proxy Statement/Prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from Quanterix or Akoya as indicated above.

No Offer or Solicitation

This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval with respect to the Merger, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.

Cautionary Statement Regarding Forward-Looking Statements

Statements included in this Current Report on Form 8-K which are not historical in nature or do not relate to current facts are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provided by Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on, among other things, projections as to the anticipated benefits of the Merger as well as statements regarding the impact of the Merger on Akoya’s business and future financial and operating results, the amount and timing of synergies from the Merger and the closing date for the Merger. Words and phrases such as “may,” “approximately,” “continue,” “should,” “expects,” “projects,” “anticipates,” “is likely,” “look ahead,” “look forward,” “believes,” “will,” “intends,” “estimates,” “strategy,” “plan,” “could,” “potential,” “possible” and variations of such words and similar expressions are intended to identify such forward-looking statements. Akoya cautions readers that forward-looking statements are subject to certain risks and uncertainties that are difficult to predict with regard to, among other things, timing, extent, likelihood and degree of occurrence, which could cause actual results to differ materially from anticipated results. Such risks and uncertainties include, among others, the following possibilities: the occurrence of any event, change or other circumstances that could give rise to the right of one or both of the parties to terminate the Merger Agreement; the outcome of any legal proceedings that may be instituted against Quanterix or Akoya; the failure to obtain approval of Akoya’s stockholders or to satisfy any of the other conditions to the Merger on a timely basis or at all; the possibility that the anticipated benefits and synergies of the Merger are not realized when expected or at all, including as a result of the impact of, or problems arising from, the integration of the two companies or as a result of the strength of the economy and competitive factors in the areas where Quanterix and Akoya do business; the possibility that the Merger may be more expensive to complete than anticipated; diversion of management’s attention from ongoing business operations and opportunities; potential adverse reactions or changes to business or employee relationships, including those resulting from the announcement or completion of the Merger; changes in Quanterix’s share price before the closing of the Merger; risks relating to the potential dilutive effect of shares of Quanterix common stock to be issued in the Merger; the ability of Akoya to repay any convertible notes and other factors that may affect future results of Quanterix, Akoya and the combined company. Additional factors that could cause results to differ materially from those described above can be found in the Proxy Statement/Prospectus, and in other documents Akoya files with the SEC, which are available on the SEC’s website at www.sec.gov.

All forward-looking statements, expressed or implied, included in this Current Report are expressly qualified in their entirety by the cautionary statements contained or referred to herein. If one or more events related to these or other risks or uncertainties materialize, or if Akoya’s underlying assumptions prove to be incorrect, actual results may differ materially from what Akoya anticipates. Akoya cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made and are based on information available at that time. Akoya does not assume any obligation to update or otherwise revise any forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements were made or to reflect the occurrence of unanticipated events except as required by federal securities laws.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: June 2, 2025	Akoya Biosciences, Inc.

	By:	/s/ Brian McKelligon
		Brian McKelligon
		Chief Executive Officer

Filing Compare · Akoya Biosciences, Inc.